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The effects of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), a new antiviral drug, and acyclovir
(ACV) [9-(2-hydroxyethoxymethyl)guanine] on the replication of Epstein-Barr virus (EBV) were compared.
Both drugs inhibited EBV DNA replication in P3HR-1 cells and superinfected Raji cells, but neither
inhibited replication of the plasmid form of the EBV genome in latently infected Raji cells. However, DHPG
had a more prolonged inhibitory effect than ACV. Although the effect of the drugs is prompt, the kinetics of
inhibition of EBV replication indicated that a drug exposure of 14 days was needed to reduce the EBV
genome copy number to the residual plasmid level (30 copies per cell). The inhibitory effect of ACV was
readily reversed within 11 days after removal of the drug, in contrast to the more prolonged effect exerted by
DHPG, which persisted for more than 21 days. The 50% inhibitory doses for cell growth of ACV and DHPG
were estimated to be 250 and 200 ,uM, respectively. The viral 50% and 90% effective doses of inhibition
were, respectively, 0.3 and 9 FM for ACV and 0.05 and 3 puM for DHPG. The therapeutic indices (50%
inhibitory dose/50% effective dose) for ACV and DHPG were 833 and 4,000, respectively. Synthesis of
EBV-associated polypeptides was also affected. In superinfected Raji cells, ACV (100 F.M) and DHPG (30
,uM) inhibited synthesis of polypeptides with molecular weights of 145,000 and 140,000; in addition,
synthesis of polypeptides with molecular weights of 110,000 and 85,000 was markedly reduced by DHPG
but not by ACV. However, after drug removal, the inhibitory effect of ACV on polypeptide synthesis was
abolished in contrast to the more persistent effect of DHPG.
The hallmark of herpes group viruses is their ability to
cause latent and persistent as well as acute productive
infections. In the past few years, we have shown that
acyclovir (ACV) [9-(2-hydroxyethoxymethyl)guanine] (8)
has potent effects against Epstein-Barr virus (EBV) infec-
tions in vitro when there is active replication of the virus (5,
12, 14). However, ACV has no effect in vitro on latent EBV
infection, nor does the drug promise to be of much use in
persistent low-level infection with EBV (20). Inasmuch as
latent and persistent infections may be key elements of the
oncogenic and chronic disease states associated with EBV,
we started searching for other anti-EBV agents with the
specific goal of identifying compounds whose effects might
be more prolonged than those of ACV. We recently reported
(17) that three nucleoside analogs, E-5-(2-bromovinyl)-2'-
deoxyuridine, 1-(2-deoxy-2-fluoro-p-D-arabinofuranosyl)-5-
iodocytosine, and 1-(2-deoxy-2-fluoro-4-D-arabinofurano-
syl)-5-methyluracil, are potent inhibitors of EBV replication
in vitro. These three drugs have prolonged effects in sup-
pressing viral replication, even after the drugs are removed
from persistently infected cell cultures (17).
Recently, an ACV congener, 9-(1,3-dihydroxy-2-propoxy-
methyl)guanine (DHPG), was reported to have anti-herpes
simplex virus types 1 and 2 (HSV-1 and HSV-2) activity with
a marginal activity against EBV and no activity against
human cytomegalovirus (CMV) (24). However, we have
found that DHPG is active not only against replication of
HSV-1 and HSV-2 but also against CMV and EBV (3). In
addition, certain variants of HSV which induced altered
virally coded thymidine kinase and DNA polymerase and
had become resistant to ACV were still as sensitive to
DHPG as was the parental virus (3). In view of these results,
we decided to extend our findings and characterize the
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efficacy of DHPG in parallel with ACV in terms of inhibition
of replication of EBV in human lymphoblastoid cell lines.
The results clearly indicate that DHPG is more potent and
has a more prolonged inhibitory effect than ACV.
MATERIALS AND METHODS
Cell cultures. Virus producer (P3HR-1) and nonproducer
(Raji) cells were grown in tissue culture flasks in RMPI 1640
medium as described previously (13). A steady-state mode of
growth was established as follows. Cells were seeded at a
density of 4 x 105 to 6 x 105 cells per ml and were counted
daily until they reached a density of 3 x 106 cells per ml.
During this interval, the cells were growing in a strictly
exponential fashion (15).
Treatment of cells with drugs. Exponentially growing cells
were spun down and suspended in fresh medium containing
different concentrations of drugs for an appropriate time as
indicated. At the end of drug treatment, cells were harvest-
ed, and the number of EBV genome copies per cell was
determined. In some experiments, the drug-treated cells
were released into drug-free medium and incubated for an
appropriate time as specified in the figures.
Determination of 50% inhibitory dose (ID50) for cell growth.
During drug treatment, cells were counted daily. Cell viabili-
ty was determined by the trypan blue exclusion method. The
number of cells after 4 days of growth was plotted against
drug concentration on a semilogarithmic scale. The cell
growth ID50 was that concentration of drug that inhibited cell
growth by 50% after 4 days compared with the no-drug
control.
Determination of EBV genome copies per cell. EBV DNA
was purified from virus isolated from the supernatant fluids
of 12-O-tetradencanoylphorbol-13-acetate-induced P3HR-1
cells as previously reported (13, 14). In vitro synthesis of
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cRNA and cRNA-DNA hybridization on nitrocellulose fil-
ters was carried out as described elsewhere (15, 16).
Determination of viral ED50 and ED". The number of EBV
genome copies per cell after drug treatment was plotted
against drug concentrations. The viral 50% and 90% effective
doses (ED5os and ED"os) of inhibition were those concentra-
tions of drug that inhibited viral DNA replication by 50 and
90%, respectively, compared with the no-drug control.
Superinfection of Raji cells with P3HR-1 virus. Virus used
for superinfection of Raji cells was prepared from 12-0-
tetradecanoylphorbol-13-acetate-induced P3HR-1 culture
fluids (13). Virus harvested from 1.5 liters of fluids by
centrifugation (13,000 x g for 90 min in a GS-3 rotor) was
suspended in 6 ml of RPMI 1640 medium containing 2% fetal
calf serum and stored at -70°C. For superinfection, 106 Raji
cells in exponential growth were pelleted and suspended in 1
ml of RPMI 1640 medium containing 2% serum and an
appropriate amount of virus (time zero). After 1 h at 37°C in
a CO2 incubator, the cells were pelleted, washed twice with
phosphate-free minimal essential medium, and suspended in
1 ml of the same buffer containing 2% dialyzed fetal calf
serum and 100 ,uM ACV or 30 p.M DHPG. At 6 h postinfec-
tion, 200 ,uCi of 32p was added, and incubation continued
until 24 h after infection. For radiolabeling polypeptides,
after viral absorption cells were starved in methionine-free
minimal essential medium containing 2% dialyzed fetal calf
serum for 5 h; then [35S]methionine (50 ,uCi/ml) was added.
Labeling was continued for 24 h after infection.
Equilibrium density centrifugation. Both superinfected and
mock-infected Raji cells were pelleted, and DNA was isolat-
ed and processed for analysis in cesium chloride density
gradients as described previously (15).
Polylacrylamide gel electrophoresis. The [35S]methionine-
labeled proteins were analyzed on slab gels in Laemmli's
system (11). The proteins were treated with sample buffer
and electrophoresed at 25 mA per slab for 8 h. Radiolabeled















Effects of ACV and DHPG on cell growth. Both Raji and
P3HR-1 cells were cultured in the presence of various
concentrations of ACV and DHPG. The growth curves of
P3HR-1 cells in the presence of the drugs are shown in Fig.
1. Both ACV (Fig. 1A) and DHPG (Fig. 1B) at concentra-
tions of .10 ,uM had slight effects on cell multiplication. At
100 ,uM ACV and DHPG, there was cell multiplication, but
the total cell counts after 4 days of cell growth were 35 and
40%, respectively, below those in control (drug-free) cul-
tures. The viability of cells was maintained at 95% in all
concentrations of ACV and DHPG tested. A wide range of
drug concentrations was used to determine the concentra-
tion that inhibited cell growth by 50% (ID50). The ID50 for
cell growth was determined by plotting the concentration of
drug against the number of cells after 4 days of growth. In
these studies, the ID50s for ACV and DHPG were 250 and
200 ,uM, respectively. Similar values were obtained for Raji
cells under the same experimental conditions (data not
shown).
Determination of viral ED50 and ED". Figure 2 shows the
dose-dependent effects of ACV and DHPG on viral genomes
in P3HR-1 cells cultured for 14 days in the presence of drugs;
EBV genome copies per cell decreased with increasing drug
concentrations in both cases but at different rates. The viral
ED50 and ED90 were determined from the semilogarithmic
plot of drug concentrations against viral genome copies per
cell, assuming the residual genome level (30 copies per cell)
achieved by an effective drug concentration (100 ,uM) as zero
and the viral genome level before drug treatment as 100. The
ED50 and ED90 thus obtained were, respectively, 0.3 and 9
puM for ACV and 0.05 and 3 p.M for DHPG. On the basis of
these data and the cell ID50 values, we calculated the
therapeutic indices (ID5sED50) as 833 and 4,000 for ACV
and DHPG, respectively.
Concentrations of the drugs 10 times greater than the ED90
DAYS DAYS
FIG. 1. Effect of ACV and DHPG on the proliferation of P3HR-1 cells in culture.
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FIG. 2. Determination of viral ED50 and ED90 of ACV and
DHPG. Exponentially growing P3HR-1 cells were seeded at a
density of 106 per ml and incubated in various concentrations of
drugs for 14 days. EBV genome copy numbers per cell determined
at each drug concentration were the average of two determinations.
ACV: ED50 = 0.3 ,uM, ED90 = 9 p.M; DHPG: ED50 = 0.05 ,M,
EDo= 3 ,uM.
did not affect the EBV DNA coptent of nonproducer Raji
cells (data not shown).
Effects of ACV and DIJPG on superinfected Raji cells. To
establish that the inhibitory effect of DHPG on EBV DNA
replication is a general phenomenon and is not limited to one
kind of cell system, we tested the drugs in a superinfected
Raji cell system. Superinfection of Raji cells with P3HR-1
virus results in shutdown of host functions and stimulation of
viral DNA synthesis.(18). A large quantity of EBV DNA was
synthesized after superinfection of Raji cells (Fig. 3A) as
measured by the radioactivity incorporated into DNA band-
ing at 1.718 g/cm3, the density of viral DNA. In contrast,
viral DNA replication was greatly reduced in the presence of
100 ,uM ACV (Fig. 3B) and 30 ,uM DHPG (Fig. 3C).
Kinetics of inhibition ofEBV genome replication and revers-
ibility. Our previous work (3) and th'e present study (Fig. 2)
indicated that 30 ILM DHPG was equivalent to 100 ,uM ACV
(10-fold ED9o) in inhibition of EBV DNA synthesis. We next
compared the inhibitory effects ofACV (100 p.M) and DHPG
(30 FLM) in P3HR-1 cells. We determined the kinetics of
reduction of EBV genome replication by growing the cells in
drug-containing medium. At various intervals, samples of
cells were taken and viral genome copies per cell were
determined. EBV genome numbers were rapidly reduced
from 390 to 60 copies per cell after 7 days of exposure to
ACV (Fig. 4A). By 14 days, the viral genome copies per cell
were reduced to 30 and stably maintained at this low level for
42 days under continuous exposure to the drug. However,
the inhibitory effect of ACV was readily reversed upon
removal of the drug (Fig. 4B). Viral genome replication
returned to the original level by 11 days after release of the
cells into drug-free medium.
Identical experiments were carried out for DHPG (Fig. 5).
Again, 14 days were needed to reduce the viral genome
number to the minimum residual level (30 copies per cell).
However, upon removal of the drug, the viral genorne copies
per cell remained at low levels for 14 days, becoming
gradually restored and reaching 23% of the control value by
21 days. Eventually, the genome numbers returned to con-
trol levels of untreated cells after 42 days (data not shown).
0
I
Differential effects of ACV and DHPG on synthesis of EBV-
associated polypeptides. We compared the effects of ACV
and DHPG on the synthesis of virus-associated polypep-
tides. Figure 6 shows the results of a fluorogram made by
exposing an electropherogram of 35S-labeled polypeptides
synthesized in superinfected Raji cells in the presence and
absence of drugs. Superinfection of Raji cells (lane D), as
compared with mock-infected cells (lane C), resulted in the
synthesis of at least seven new polypeptides of molecular
weights 145,000 (145K), 140K, 135K, 110K, 85K, 55K, and
32K detected 24 h postinfection in a continuous labeling
experiment. In the presence of 30 ,uM DHPG (lane E) and
100 FM ACV (lane A), synthesis of polypeptides of molecu-
lar weights 145K and 140K were significantly inhibited in
both cases. In addition, synthesis of polypeptides 110K and
85K was markedly reduced by DHPG but not by ACV.
When ACV was removed 6 h posttreatment, synthesis of the
145K and 140K polypeptides resumed (lane B). In contrast,
the inhibitory effect of DHPG on polypeptides of 145K,
140K, 110K, and 85K persisted even after drug removal
(lane F).
IDISCUSSION
DHPG has several features that make it a potentially
valuable and unique antiviral drug: broad spectrum of effect
against all of the human herpesviruses including CMV,
heightened activity against HSV, and activity against some
ACV-resistant HSV mutants. In this study, we have clearly
shown that DHPG has a more prolonged inhibitory effect
against EBV than does its parental compound, ACV, yet the
drug is nontoxic with a very high therapeutic index in cell
culture. As with ACV, the EBV plasmids in the nonvirus-
producing cell line (Raji), as well as in the nonproductive
fraction of the P3HR-1 cells, are not affected by this drug.
Since there is no plaque assay for EBV, determinations of
ED50 have to be done differently than those for HSV. Precise
estimates can be made by measurements of genome numbers
through nucleic acid hybridization techniques.
The viral ED50 and ED90 were 0.3 and 9 puM for ACV,
respectively, and 0.05 and 3 p,M for DHPG (Fig. 2). Our
previous estimate of the ED50 of ACV was 6 ,uM (5). This
value represents a 20-fold underestimation compared with
the present results (0.3 ,uM). This discrepancy is probably
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FIG. 3. Inhibition of EBV DNA replication by ACV (100 ,uM)
and DHPG (30 ,uM) in superinfected Raji cells. EBV DNA replica-
tion was determined by measuring the incorporation of 32p into viral
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FIG. 4. Kinetics of inhibition and reversibility of EBV DNA replication in P3HR-1 cells treated with ACV.
instead of 7 days as done by Colby et al. (5); and (ii) taking as
the zero point the residual level of 30 genome copies per cell.
Depending upon the cells used, the ED50 values of ACV for
HSV-1 (as determined by plaque reduction assay) were 0.1
,uM in Vero cells (23) and 0.7 ,uM in HeLa cells (6). Our new
results put the level of sensitivity of EBV to ACV in the
same range as that of HSV. The ED50 of DHPG for EBV
estimated from the data in our previous report (3) was
approximately 1 puM. This value was obtained by treating the
P3HR-1 cells with various concentrations of DHPG for only
5 days, which is not enough time for linear genomes already
synthesized before the addition of drug to become undetect-
able.
The inhibition of EBV DNA replication in P3HR-1 cells at
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FIG. 5. Kinetics of inhibition and reversibility of EBV DNA
replication in P3HR-1 cells treated with DHPG.
that a virus-specific function is affected. Inhibition of growth
of the host cell requires 833- and 4,000-fold (ID50/ED50)
greater concentrations of ACV and DHPG, respectively,
than does the inhibition of viral multiplication. These results
and our previous report clearly show that DHPG could
effectively inhibit the replication of HSV-1, HSV-2, CMV,
and EBV (3) at noncytotoxic concentrations. These observa-
tions are in contrast to a recent report by Smith et al. (24)
which indicated a lack of activity against EBV and CMV at
the noncytotoxic concentration. The potent anti-EBV and
anti-CMV activity of DHPG may have been overlooked by
these investigators since they examined the effect of DHPG
on the expression of virus-specific antigens which were
expressed despite inhibition of viral DNA synthesis. More-
over, the assays (immunofluorescence and radio-
immunoassay) that they employed are generally less sensi-
tive and less quantitative than cRNA-DNA hybridization.
Studies on the activity of DHPG against drug-resistant
HSV-1 mutants, both at the thymidine kinase (TK) and DNA
polymerase loci, clearly indicate that the virus-induced TK
plays an important role in the action ofDHPG against HSV-1
(3, 24). We have shown previously that an HSV-1 mutant
(MDK strain) which could not induce TK in infected cells
was resistant to DHPG (3). However, HSV mutants (B3,
Tr7, S1) that induced an altered TK with no apparent change
of induced DNA polymerase in infected cells were still
sensitive to DHPG, despite the fact that those mutants were
resistant to ACV (3). Thus, mutation to resistance to ACV
due to alteration of viral TK does not necessarily result in
resistance to DHPG. These results suggest that DHPG is less
fastidious in its TK requirements than is ACV.
There is some evidence for and against the existence of an
EBV-specific TK (2, 4, 7, 19, 20). However, there has been
no unequivocal demonstration of a novel enzyme activity
induced by EBV that might represent a virally coded TK. It
remains to be established whether the inhibition of EBV
replication by ACV and DHPG follows a mechanism similar
to that reported in HSV (8).
Consistent with the prolonged inhibition of EBV DNA
synthesis by DHPG is the demonstration of the more sus-
tained and differential effects of DHPG on EBV-associated
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FIG. 6. Differential effects of ACV and DHPG on synthesis of
EBV-associated polypeptides. Lanes: A, polypeptides synthesized
in superinfected Raji cells, in the continuous presence of ACV (100
,uM); B, same as A except that ACV was removed at 6 h posttreat-
ment; C and D, respectively, mock-infected and superinfected Raji
cells in the absence of drugs; E, polypeptides synthesized in
superinfected Raji cells in the continuous presence of DHPG (30
,uM); F, same as E except that DHPG was removed at 6 h
posttreatment.
polypeptides. Although both DHPG and ACV inhibit synthe-
sis of at least two EBV-induced polypeptides (molecular
weights 145K and 140K), the inhibitory effect of ACV was
abolished, in contrast to the persistent effect of DHPG after
drug removal. Of interest is the additional effect on the
synthesis of polypeptides with molecular weights of 110K
and 85K exerted by DHPG but not by ACV. These findings
are similar to our previous work on differential effects of
DNA inhibitors on viral polypeptide synthesis (9). As is the
case for other antiviral drugs, the effect of DHPG on viral
polypeptides is most likely due to inhibition of EBV DNA
synthesis. Thus, the greater persistent effect ofDHPG on the
synthesis of virus progeny DNA that can serve as template
for mRNA may be responsible for the decrease in synthesis
of these polypeptides (22). The differential reduction in
EBV-induced polypeptide synthesis, although a secondary
effect of the drug, could play a role in the inhibition of virus
replication, as suggested in HSV systems (10, 21).
Despite the structural similarities of ACV and DHPG,
DHPG appears to have a more potent and prolonged inhibi-
tory effect against EBV than does ACV. Whether these
effects are due to the differences in drug metabolism (phos-
phorylation) or to relative effects in incorporation of the
drugs into DNA and chain termination remains to be deter-
mined. The greater antiviral activity in comparison with
existing antiherpes compounds, the very low cytotoxicity,
the higher solubility in water (24), and the more persistent
effect make DHPG a promising candidate for clinical trial if
the drug is nontoxic in animal studies.
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